Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "SWOG S1929 Phase II Randomized Study - Maintenance Atezo vs. Atezo + Talazoparib in Patients With SLFN11+ ES-SCLC"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Nagla Abdel Karim
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Nagla Abdel Karim
Login to view comments.
Click here to Login
